China Universal Asset Management Co., Ltd. Rain Therapeutics Inc. Transaction History

China Universal Asset Management Co., Ltd.

  • $700 Million
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 21, 2022
BUY
$4.75 - $8.01 $836 - $1,409
176 New
176 $1,000

Others Institutions Holding RAIN

# of Institutions
3
Shares Held
122K
Call Options Held
0
Put Options Held
0
View Full List

About Rain Therapeutics Inc.

RAIN Quotes by TradingView
  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email